BrahMos WORLD INDIA MADHYA PRADESH BHOPAL WTN SPECIAL GOSSIP CORNER RELIGION SPORTS BUSINESS FUN FACTS ENTERTAINMENT LIFESTYLE TRAVEL ART & LITERATURE SCIENCE & TECHNOLOGY HEALTH EDUCATION DIASPORA OPINION & INTERVIEW RECIPES DRINKS BIG MEMSAAB 2017 BUDGET 2017 FUNNY VIDEOS VIRAL ON WEB PICTURE STORIES Mahakal Ke Darshan
WTN HINDI ABOUT US PRIVACY POLICY SITEMAP CONTACT US
logo
Breaking News

Dr Reddy s Q4 net up by 175 per cent

Friday - May 12, 2017 7:54 pm , Category : BUSINESS
 Dr Reddy s Q4 net up by 175 per cent
Dr Reddy s Q4 net up by 175 per cent

Hyderabad May 12 (IANS) The net profit of pharma major Dr Reddy s Laboratories jumped 175 per cent to Rs 337.6 crore for the fourth quarter ended March 31.

The company had posted a net profit of Rs 122.6 crore for the corresponding period of the previous fiscal.

Its consolidated total income declined by 4.8 per cent to Rs 3 554 crore against Rs 3 756 crore in the same quarter last fiscal.

For the full year ended March 2017 the net profit fell by 40 per cent to Rs 1 203 crore against Rs 2 001 crore in 2015-16.

The Hyderabad-based company on Friday announced results for Q4 and the financial year 2016-17.

Revenues for the full year too decreased by 9 per cent to Rs 14 080 crore from Rs 15 470 crore in the previous fiscal.

FY17 has been a challenging year due to lack of new product approvals for the US market. However our other geographies delivered good performances with several new product launches said G.V. Prasad Co-chairman and CEO Dr Reddy s.

The company attributed decrease in revenue and profit to 10 per cent and 5 per cent decline in revenues from global generics and pharmaceutical services and active ingredients segments respectively.

Global generics sales during Q4 slipped 5 per cent over the previous quarter to Rs 2 913.8 crore while North America generic sales dropped 8 per cent to Rs 1 534.9 crore.

Europe generic sales during the quarter dropped 4 per cent to Rs 206.6 crore and India sales also declined 4 per cent to Rs 571.1 crore compared with Q3 of FY17.

The board of directors recommended a final dividend of Rs 20 (400 per cent) per equity share of Rs 5 face value for the financial year 2016-17.

--IANS
ms/lok/dg